Regeneron Pharmaceuticals, Inc.
REGN
#294
Rank
$83.887 B
Marketcap
United States
Country
$814.79
Share price
2.23%
Change (1 day)
33.36%
Change (1 year)
Categories
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic…
Key Metrics
Trailing P/E
19.41
Forward P/E
12.94
EPS (TTM)
$40.42
Forward EPS
$60.62
Price / Book
2.48
EV / EBITDA
15.6x
Beta
0.19
Dividend Yield
0.48%
Return on Equity
14.04%
Return on Assets
6.53%
Debt / Equity
8.54
Current Ratio
3.33
Gross Margin
44.46%
Operating Margin
33.11%
Net Profit Margin
27.87%
Free Cash Flow
$3.065B
Charts
Price history and financial performance over time.
Price & Market Cap
Aug 19 – Sep 18
-6.68%
Source: Yahoo Finance daily closes. Market cap uses the closest quarterly shares-outstanding filing for each date.
Revenue & Net Income
Annual · USD
RevenueNet Income
Latest Revenue$14.343B
Latest Net Income$4.505B
Reporting periods4
Source: Yahoo Finance annual income statements. Year is the fiscal-year end. Most recent period may be trailing-twelve-month (TTM) until the next 10-K is filed.
Compare Regeneron Pharmaceuticals, Inc. with competitors
Side-by-side market cap, revenue, and financial comparison.
Latest News
Latest News
REGN
No recent news available. Set FINNHUB_API_KEY to enable news.
